Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.dsx.2020.03.016 http://scihub22266oqcxt.onion/10.1016/j.dsx.2020.03.016 32283499!7144598!32283499     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Metab+Syndr 2020 ; 14 (4): 283-287 Nephropedia Template TP {{tp|p=32283499|t=2020. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers |pdf=|usr=}}{{32283499}} gab.com Text Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers JO: Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32283499 #FOAvip BACKGROUND AND AIMS: COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB). METHODS: We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words. RESULTS: From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2. CONCLUSION: Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider. Twit Text FOAVip Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers ????Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32283499 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32283499 #FOAvip English Wikipedia <ref>{{Cite pmid|32283499}}</ref> Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers #MMPMID32283499 Singh AK; Gupta R; Misra A Diabetes Metab Syndr 2020[Jul]; 14 (4): 283-287 PMID32283499show ga BACKGROUND AND AIMS: COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB). METHODS: We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words. RESULTS: From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2. CONCLUSION: Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider. |*Betacoronavirus[MESH] |*Comorbidity[MESH] |Angiotensin Receptor Antagonists/adverse effects/therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use[MESH] |Animals[MESH] |Antihypertensive Agents/adverse effects/*therapeutic use[MESH] |COVID-19[MESH] |Cardiovascular Diseases/epidemiology[MESH] |China/epidemiology[MESH] |Coronavirus Infections/*epidemiology/mortality[MESH] |Diabetes Mellitus/epidemiology[MESH] |Humans[MESH] |Hypertension/*drug therapy/epidemiology[MESH] |Mice[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/physiology[MESH] |Pneumonia, Viral/*epidemiology/mortality[MESH] |PubMed[MESH] |Renin-Angiotensin System/*drug effects/physiology[MESH]Comorbidities in COVID-19: Outcomes in hypertensive cohort and controv(epmc).pdf DeepDyve Pubget Overpricing